Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H27N5O6 |
| Molecular Weight | 433.4583 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC(=O)N[C@@H](CNC(=O)C[C@H]1CC(=NO1)C2=CC=C(C=C2)C(N)=N)C(O)=O
InChI
InChIKey=SRRJCHGGTPFZSS-ZBFHGGJFSA-N
InChI=1S/C20H27N5O6/c1-2-3-8-30-20(29)24-16(19(27)28)11-23-17(26)10-14-9-15(25-31-14)12-4-6-13(7-5-12)18(21)22/h4-7,14,16H,2-3,8-11H2,1H3,(H3,21,22)(H,23,26)(H,24,29)(H,27,28)/t14-,16+/m1/s1
| Molecular Formula | C20H27N5O6 |
| Molecular Weight | 433.4583 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Roxifiban (also known as DMP754), a potent antiplatelet agent in inhibiting platelet aggregation, and has a high specificity and affinity for human platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa) receptors. Roxifiban participated in clinical trials phase III for the treatment of peripheral arterial disorders. This drug was also well tolerated in patients with chronic stable angina pectoris and was studied in the treatment of heparin-induced thrombocytopenia, and thrombosis. However, the development of this drug appears to have been discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor]. | 2017-11 |
|
| The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. | 2003 |
|
| Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis. | 2002-04 |
|
| Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates. | 1998-03-01 |
Patents
Sample Use Guides
Ninety-eight patients were randomized to receive either a placebo or 1 of 8 oral dosages of roxifiban. Twenty-two patients were enrolled in multiple-dose regimens, bringing the total study population to 120. The oral dosages were 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, or 2.5 mg/day for up to 30 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 17:27:58 GMT 2025
by
admin
on
Wed Apr 02 17:27:58 GMT 2025
|
| Record UNII |
R96EWZ6KUZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
170902-52-0
Created by
admin on Wed Apr 02 17:27:58 GMT 2025 , Edited by admin on Wed Apr 02 17:27:58 GMT 2025
|
PRIMARY | |||
|
177231
Created by
admin on Wed Apr 02 17:27:58 GMT 2025 , Edited by admin on Wed Apr 02 17:27:58 GMT 2025
|
PRIMARY | |||
|
DTXSID80168970
Created by
admin on Wed Apr 02 17:27:58 GMT 2025 , Edited by admin on Wed Apr 02 17:27:58 GMT 2025
|
PRIMARY | |||
|
R96EWZ6KUZ
Created by
admin on Wed Apr 02 17:27:58 GMT 2025 , Edited by admin on Wed Apr 02 17:27:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
